Literature DB >> 2469896

Hypertension in the elderly: the role of calcium antagonists.

J P Chalmers1, S A Smith, L M Wing.   

Abstract

Calcium antagonists have a spectrum of actions that opposes many of the pathophysiological abnormalities found in hypertension in old age. There is good evidence that these drugs reduce blood pressure effectively in the elderly. There is no evidence from controlled studies to indicate that they are more effective in elderly than in young subjects. There is equally no convincing evidence that age is an independent predictor of hypotensive efficacy of calcium channel antagonists, after the effect of pretreatment blood pressure and random variation have been taken into account. There have been no studies comparing the efficacy of calcium antagonists with other classes of antihypertensive drugs in old age, and there is no evidence that any one group of calcium antagonists is superior in this age group. There have been no studies demonstrating that calcium antagonists have a beneficial effect on the morbidity and mortality associated with hypertension in the elderly, or indeed in any age group. Side effects are equally common in old and young subjects and are usually mild. Overall, calcium antagonists are valuable and appropriate drugs for the treatment of hypertension in the elderly. They may be particularly useful for treating hypertension associated with conditions that occur with increased frequency in the elderly such as peripheral vascular disease, ischemic heart disease, cardiac arrhythmias, and obstructive airways disease. Since plasma concentrations of these drugs may be elevated in elderly patients due to altered pharmacokinetics, therapy should be started with low doses and increased gradually.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2469896

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  Hypertension in the elderly.

Authors:  P Larochelle
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  The preparation and acute antihypertensive effects of a nanocapsular form of darodipine, a dihydropyridine calcium entry blocker.

Authors:  B Hubert; J Atkinson; M Guerret; M Hoffman; J P Devissaguet; P Maincent
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

4.  Adverse effects using combined rate-slowing antihypertensive agents.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-06-20       Impact factor: 3.738

Review 5.  Choosing the optimum therapy for older hypertensive patients.

Authors:  W H Birkenhäger
Journal:  Drugs Aging       Date:  1991-01       Impact factor: 3.923

Review 6.  Calcium antagonists in the elderly.

Authors:  J G Kelly; K O'Malley
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.